Chronic ecstasy use increases neurotrophin-4 gene expression and protein levels in the rat brain

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 998-1004

  Hatami, Homeira ^a   Hossainpour Faizi, Mohammad Ali ^a   Azarfarin, Maryam ^b   Azarfam, Parvin ^a  

^a UNIVERSITY OF TABRIZ   (Iran)

^b UNIVERSITY OF MOHAGHEGH ARDABILI   (Iran)

Author keywords

Addiction; Ecstasy; ELISA; Gene expression; NT 4

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BETA ACTIN; MESSENGER RNA; NEUROTROPHIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN REGION; BRAIN STEM; CEREBELLUM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG DEPENDENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEMISPHERE; MALADJUSTMENT; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 79551478773     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70361-3     Document Type: Article

References (35)

1. Akbarian S, Maribel R, Rng-Jian L, Stephen JG, Hiu-Fai F: Brain-derived neurotrophic factor is essential for opiate induced plasticity of noradrenergic neurons. J Neurosci, 2002, 22, 4153-4162.
2. Barbacid M: Structural and functional properties of the TRK family of neurotrophin receptors. Ann Rev Neurosci, 2001, 24, 677-736.
3. 75 receptors. J Biol Chem, 1999, 271, 21100-21107.
4. Bolanos CA, Nestler EJ: Neurotrophic mechanisms in drug addiction. Neuromolecular Med, 2005, 5, 69-83.
5. Camp DM, Browman KE, Robinson TE: The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fisher 344 rats. Brain Res, 1994, 668, 180-193.
6. Chao MV: Neurotrophins and their receptors: a convergence point for many signaling pathways. Nat Rev Neurosci, 2003, 4, 299-309.
7. Corominas M, Roncero C, Ribases M, Castells X, Casas M: Brain-derived neurotrophic factor and its intracellular signaling pathways in cocaine addiction. Neuropsychobiology, 2007, 55, 2-13.
8. Daly EE, Chefer V, Sandill S, Shippenberg TS: Modulation of the neurotoxic effects of methamphetamine by the selective κ-opioid receptor agonist U69593. J Neurochem, 2000, 74, 1553-1562.
9. Desmond S, Leil J, Tarek A, Xin L: Neurotrophin-4 is required for tolerance to morphine in the mouse. Neurosci Lett, 2003, 340, 103-106.
10. Durany N, Michel T, Zöchling R, Boissl KW, Cruz-Sánchez FF, Riederer P, Thome J: Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res, 2001, 52, 79-86.
11. Fleckemstein AE, Gibb JW, Hanson G: Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol, 2000, 406, 1-13.
12. Green AR, Mechan AQ, Elliot JM, O'Shea E, Colado MI: The pharmacology and clinical pharmacology of MDMA. Pharmacol Rev, 2003, 55, 463-508.
13. Hatami H, Oryan Sh, Semnanian S, Kazemi B, Ahmadiani A: Additive effect of dextromethorphan on the inhibitory effect of anti-NT4 on morphine tolerance. Pharmacology, 2006, 78, 105-112. (Pubitemid 44764025)
14. Hatami H, Oryan Sh, Semnanian S, Kazemi B, Bandepour M, Ahmadiani A: Alteration of BDNF and NT-3 genes expression in the nucleus paragigantocellularis during morphine dependency and withdrawal. Neuropeptides, 2007, 41, 321-328. (Pubitemid 47247863)
15. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM: BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature, 1991, 350, 230-232. (Pubitemid 21912205)
16. Koob GF, Sanna PP, Bloom FE: Neuroscience of addiction. Neuron, 1998, 21, 467-476.
17. Koprich JB, Campbell NG, Lipton JW: Neonatal 3,4- methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases BDNF in the forebrain and brainstem of the rat. Brain Res Dev Brain Res, 2003, 147, 177-182.
18. Lu B: Acute and long-term synaptic modulation by neurotrophins. Prog Brain Res, 2004, 146, 137-150.
19. Miquel M, Toledo R, Garcia LI, Coria-Avila GA, Manzo J: Why should we keep the cerebellum in mind when thinking about addiction? Curr Drug Abuse Rev, 2009, 2, 26-40.
20. Nagai F, Nonaka R, Satoh K, Kamimura H: The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol, 2007, 559, 132-137. (Pubitemid 46295399)
21. Narita M, Aokl K, Takagl Y: Implication of BDNF in the release of dopamine and dopamine-released behaviors induced by methamphetamine. Neuroscience, 2003, 119, 767-775.
22. Nestler EJ: Molecular mechanisms of drug addiction. Neuropharmacology, 2004, 47, Suppl 1, 24-32.
23. Nestler EJ, Hope BT, Widnell KL: Drug addiction: a model for the molecular basis of neural plasticity. Neuron, 1993, 11, 995-1006.
24. Parrott AC: Chronic tolerance to recreational MDMA or ecstasy. J Psychopharmacol, 2005, 19, 71-83.
25. Patapoutian A, Reichardt LF: Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol, 2000, 11, 272-280.
26. Pierce RC, Pierce Bancroft AF, Prasad BM: Neurotrophin-3 contributes to the initiation of behavioral sensitization to cocaine by activating the ras/mitogen-activated protein kinase signal transduction cascade. J Neurosci, 1999, 19, 8685-8695.
27. Pu L, Liu QS, Poo MM: BDNF-dependent synaptic sensitization in midbrain dopamine neurons after cocaine withdrawal. Nat Neurosci, 2006, 9, 605-607.
28. Rodriguez Fermepin M, Trinchero M, Minetto J, Beltrán A, Fernández BE: Brain derived neurotrophic factor and neurotrophin-4 employ different intracellular pathways to modulate norepinephrine uptake and release in rat hypothalamus. Neuropeptides, 2009, 43, 275-282.
29. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS: Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, 2001, 39, 32-41.
30. Schmidt CJ, Black CK, Taylor VL: Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Eur J Pharmacol, 1990, 181, 59-70.
31. Sperling W, Frank H, Martus P, Mader R, Barocka A, Walter H, Lesch OM: The concept of abnormal hemispheric organization in addition research. Alcohol Alcohol, 2000, 35, 394-399.
32. Stephan DB, Wade GR: Associative short-term synaptic plasticity mediated by endocannabinoids. Neuron, 2005, 45, 419-431.
33. Uhl GR, Liu QR, Walther D, Hess J, Naiman D: Polysubstance abuse vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. Am J Hum Genet, 2001, 69, 1290-1300.
34. Xie CW, Sayah D, Chen QS, Wei WZ, Smith D, Liu X: Deficient long-term memory and long-lasting long-term potentiation in mice with a targeted deletion of neurotrophins-4 gene. Proc Natl Acad Sci USA, 2000, 97, 8116-8121.
35. Zhang Y, Loonam TM, Noailles PA, Angulo JA: Comparison of cocaine- and methamphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions. Ann NY Acad Sci, 2001, 937, 93-120.